Across TCGA pan-cancer cohorts, CDC42SE1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDC42SE1 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDC42SE1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CDC42SE1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where CDC42SE1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.542	0.793	.038	6	view →
LSCC	OS	Median	All	1.000	0.944	.022	6	view →
LUAD	DFS	Quartile	III,IV	0.287	0.866	.024	3	view →
HNSC	DFS	Median	All	0.740	0.558	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CDC42SE1 tumor-vs-normal RNA expression · all CDC42SE1 data types